Vcanbio Cell & Gene Engineering Corp Ltd

Vcanbio Cell & Gene Engineering Corp Ltd maintains a strong liquidity position, with a current ratio of 1.82, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity is rated as medium, and its debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing. In terms of profitability, the company's return on equity (ROE) is 3.07%, and its return on assets (ROA) is 2.15%. These figures are below the industry median for ROE and ROA in the Biotechnology sector, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if its primary market experiences a downturn. Looking ahead, the company's growth trajectory appears modest. Based on the available financial data, there is no indication of significant revenue growth in the current or next fiscal year. The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets, which may impact future growth potential. The company's risk profile is characterized by a low dilution risk, with no significant dilution sources identified in the available data. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints if cash flow from operations does not improve. Recent events, including filings and transcripts, are not detailed in the available data. However, the company's ESG profile shows a high social pillar score of 8.97 and a moderate governance score of 38.89, with a perfect ESG controversies score of 100.00, indicating no major controversies.